A Compassionate Use (CU) Program of Odronextamab
- Conditions
- Relapsed or Refractory (R/R) Follicular Lymphoma (FL)Diffuse Large B-Cell Lymphoma (DLBCL)B-Cell Non-Hodgkin Lymphoma (NHL)High-Grade B-Cell Lymphoma (HGBCL)
- Registration Number
- NCT05619367
- Lead Sponsor
- Regeneron Pharmaceuticals
- Brief Summary
Provide compassionate use of odronextamab
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- AVAILABLE
- Sex
- Not specified
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- EXPANDED_ACCESS
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie odronextamab's efficacy in R/R follicular lymphoma and DLBCL?
How does odronextamab compare to standard-of-care therapies in B-cell NHL and HGBCL outcomes?
Which biomarkers correlate with response to odronextamab in Regeneron's expanded access program?
What adverse events are associated with odronextamab in compassionate use lymphoma trials?
Are there combination therapies or competitor drugs targeting CD20/CD3 in R/R B-cell lymphomas?